Agios Pharmaceuticals | AGIO - Operating Expenses


Agios Pharmaceuticals reported $130.77M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
Arrowhead Research USD 215M 8.23M Mar/2026
Astellas Pharma JPY 489.36B 52.69B Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
Bayer EUR 9.88B 452M Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
Eli Lilly USD 10.02B 285M Mar/2026
Exelixis USD 359.47M 3.28M Mar/2026
Gilead Sciences USD 23.52B 18.55B Mar/2026
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Incyte USD 5.62B 4.5B Mar/2026
Ionis Pharmaceuticals USD 364M 54M Mar/2026
Merck USD 18.17B 8.01B Mar/2026
Moderna USD 1.78B 242M Mar/2026
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Novartis USD 9.29B 507M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026